Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3197591 | 0.89 | SLC6A3 (0.55) | SLC6A3SLC6A2ESR2SLC6A4NR1H2 | |
| SCHEMBL3197517 | 0.88 | SLC6A3 (0.54) | SLC6A3SLC6A2ESR2NR1H2 | |
| SCHEMBL7052243 | 0.86 | SLC6A3 (0.58) | SLC6A3SLC6A2ESR2SLC6A4NR1H2 | |
| SCHEMBL1750511 | 0.84 | ESR2 (0.53) | SLC6A3SLC6A2ESR2SLC6A4NR1H2 | |
| SCHEMBL8252006 | 0.84 | SLC6A3 (0.58) | SLC6A3SLC6A2ESR2SLC6A4NR1H2 | |
| SCHEMBL13484448 | 0.84 | SLC6A3 (0.56) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL951478 | 0.83 | NR1H2 (0.47) | SLC6A3SLC6A2ESR2SLC6A4NR1H2 | |
| SCHEMBL6418231 | 0.83 | CHRM5 (0.59) | SLC6A3SLC6A2ESR2SLC6A4NR1H2 | |
| SCHEMBL8253723 | 0.83 | ESR2 (0.52) | SLC6A3SLC6A2ESR2SLC6A4NR1H2 | |
| SCHEMBL8261717 | 0.83 | CHRM2 (0.51) | SLC6A3SLC6A2ESR2SLC6A4NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691893-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-7691893-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-7691893-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | BERTANI BARBARA | 2010-02-11 | — | — | US | disclosed |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | BERTANI BARBARA | 2010-02-11 | — | — | US | disclosed |
| EP-2064186-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | Glaxo Group Limited (GB) | 2009-06-03 | — | — | EP | disclosed |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| WO-2008031772-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008031772-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114049-A1 | CHEMICAL COMPOUNDS | SLC6A2, HTR3C, SLC6A3 | SLC6A3 3/4885SLC6A2 1/4885ESR2 2388/4885 |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | SLC6A2, NPY5R, SLC6A3 | SLC6A3 3/4885SLC6A2 1/4885ESR2 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.